<DOC>
	<DOC>NCT01373151</DOC>
	<brief_summary>The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.</brief_summary>
	<brief_title>Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inadequate response to Methotrexate Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization American College of Rheumatology (ACR) global function status class 13 Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist High sensitivity Creactive protein (hsCRP) â‰¥ 0.8 mg/dL Previously received or currently receiving concomitant biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>